TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05515510

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FU-APP
Description: FU-APP is a web-based application using the guidelines and oral health recommendations provided by the current German Ratgeber 2020. It provides information related to oral health care for the parents of children between 6 to 72 months of age. An account was made on a certified online web-development platform and an application was developed on it.~This application serves as a practical guide for the parents of children under 6 years of age. It provides all the essential German guidelines related to first dental visits, expected dental findings, practical brushing technique steps, plaque disclosing activity, motivational brushing video, nutritional facts and behavioral habits to be avoided. It is a complete package of essential information and with high quality content that promotes prevention of ECC at an early age.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral health recommendations
Description: Oral health recommendations provided as usual (verbal/oral) according to the current German Ratgeber 2020

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral health recommendations
Description: Oral health recommendations provided as usual (verbal/oral) according to the current German Ratgeber 2020
Study: NCT00553527

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Humeral Stem replacement surgery
Description: Patient will receive humeral stem replacement.
Study: NCT02005237

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: 3-months exercise program tailored to the individual level of aerobic fitness. Patients will exercise on a bicycle ergometer (2-3 session per week) according to a predefined training plan with increasing duration and intensity
Study: NCT01750645

Intervention type: DRUG
Intervention: Intradetrusor Injection of Type-A Botulinum Toxin

Intervention type: OTHER
Intervention: Other interventions analyzed according to protocol
Description: * Placebo~* Different dosage of Type-A Botulinum Toxin injected~* Anticholinergic drugs
Study: NCT00520039

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: osteopathic manipulative medicine (OMM)
Description: At each of the first three study visits, all subjects in the osteopathic manipulative medicine (OMM) group will receive OMM using the prescribed protocol.
Study: NCT03454451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-006
Description: Subjects will receive escalating doses of CPI-006 administered intravenously once every 21 days until MTD is reached or until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-006 + ciforadenant
Description: Subjects will receive escalating doses of CPI-006 administered intravenously once every 21 days in combination with CPI-444 orally twice daily until MTD is reached for CPI-006 or until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-006 + pembrolizumab
Description: Subjects will receive escalating doses of CPI-006 in combination with pembrolizumab administered intravenously once every 21 days until MTD is reached for CPI-006 or until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-006
Description: Selected dose of CPI-006 administered intravenously once every 21 days until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-006 + ciforadenant
Description: Selected dose of CPI-006 administered intravenously once every 21 days, in combination with CPI-444 orally twice daily until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-006 + pembrolizumab
Description: Selected dose of CPI-006 in combination with pembrolizumab administered intravenously once every 21 days until disease progression.
Study: NCT01210482

Intervention type: DRUG
Intervention: Temsirolimus
Description: The usual adult dosage is temsirolimus 25 mg once weekly, to be administered via gradual intravenous infusion over 30\~60 minutes. The dosage is to be appropriately reduced according to patients' status.
Study: NCT04482088

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational Therapy in an Equine Environment
Description: 10 weeks of occupational therapy in an equine environment aimed at improving individual goals related to self-regulation, social communication, and play

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational Therapy in a Clinic (OTC)
Description: 10 weeks of occupational therapy in a clinic aimed at improving individual goals related to self-regulation, social communication, and play
Study: NCT02927574

Intervention type: DEVICE
Intervention: DCB

Intervention type: DEVICE
Intervention: POBA
Study: NCT03264937

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social-software management
Description: Using Wechat application, a social platform, to manage warfarin therapy in patients with mechanical valve replacement.
Study: NCT03455257

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cash Transfer
Description: The heads of households will receive a cash transfer for up to 7 family members in the home every quarter. Head of households will be expected to attend meetings every 4 months at their local community health centers led by Community Health Workers (CHW). Meetings will have 2 components: 1) children under 5 will be measured to identify children at risk of malnutrition and 2) group education sessions. There will also be monthly growth monitoring and education sessions led by CHW for a subgroup of head of households with children identified as risk of malnutrition with rapid referrals to regional tertiary clinics for any children with health problems that cannot be addressed by CHW.
Study: NCT03896581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Subjects will receive bimekizumab at pre-specified time-points.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo at pre-specified time-points.
Study: NCT02051062

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample collection
Description: One to three 5 mL blood samples will be collected from pediatric participants treated with BAT product ideally 6-24 hours after administration but within a maximum of 32 hours after administration.
Study: NCT03862092

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Salivary VZV-DNA PCR
Description: VZV-DNA PCR of saliva samples
Study: NCT02338115

Intervention type: DRUG
Intervention: Paclitaxel 80mg/m2 weekly x 12 weeks
Study: NCT02002871

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PSO-CT02 device
Description: The PSO-CT02 device is worn on the affected skin area where it irradiates the target Eczema area for 30 minutes with blue light. A contralateral eczema area is left untreated and serves as control.
Study: NCT03442231

Intervention type: DEVICE
Intervention: Journey UNI Unicompartmental Knee System
Description: Lateral or medial knee compartment replacement
Study: NCT04129294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NS-089/NCNP-02
Description: NS-089/NCNP-02 for Infusion is packaged as 50 mg/mL with 3 mL per vial. Study dosages will be infused over a 1 hour period at the following dose levels.~\[Part 1\] NS-089/NCNP-02 is administered at dose levels 1 and 3 in Cohort 1 and at dose levels 2 and 4 in Cohort 2.~Dose level 1: 1.62 mg/kg once weekly for 2 weeks; Dose level 2: 10 mg/kg once weekly for 2 weeks; Dose level 3: 40 mg/kg once weekly for 2 weeks; Dose level 4: 80 mg/kg once weekly for 2 weeks \[Part 2\] Based on the results from Part 1, two dosages are selected as study dosages in Part 2. Each selected dose are administered once a week for 24 weeks.
Study: NCT00574093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab; Verteporfin
Description: Patients will be administered Lucentis™ 0.5 mg on Day 1, at Months 1 and 2, and then as needed at intervals of at least 30 days through Month 11 based on the retreatment criteria algorithm. These patients will also be administered Visudyne® only on Day 3.
Study: NCT00528359

Intervention type: DRUG
Intervention: quetiapine or olanzapine or risperidone or aripiprazole
Study: NCT03606057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64565111
Description: Participants will receive JNJ-64565111, subcutaneously on days 2, 9, 16, and 23.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Participants will receive moxifloxacin capsule on days 1 or 27 in a nested crossover manner.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JNJ-64565111-matching Placebo
Description: Participants will receive JNJ-64565111-matching Placebo vehicle solution subcutaneously on days 2, 9, 16, and 23.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin-matching Placebo
Description: Participants will receive moxifloxacin-matching placebo capsule on days 1 and 27 in treatment group 1 and on day 1 or 27 in treatment group 2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin-matching Placebo
Description: Participants will receive moxifloxacin-matching placebo capsule on days 1 and 27 in treatment group 1 and on day 1 or 27 in treatment group 2.
Study: NCT01997801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine infusion
Description: Ketamine will be infused intraoperatively (0.25 mg/kg intravenous bolus following continuous infusion of 100 mcg/kg/hr).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NS infusion
Description: Normal saline will be infused intraoperatively.
Study: NCT01429441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocriplasmin
Description: 0.125 mg single intravitreal injection

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: Sham injection
Study: NCT02116725

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shower gel with zinc
Description: Standard shower gel (Sanex) supplemented with zinc sulfate.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Plain shower gel
Description: Standard shower gel (Sanex).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Distilled water
Description: Sterile distilled Water.
Study: NCT04554381

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JL1 antigen
Description: we hypothesis that JL1 can be used as an adjunctive marker for the initial diagnosis and the follow up of Acute Lymphoblastic Leukemia.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JL1 antigen
Description: we hypothesis that JL1 can be used as an adjunctive marker for the initial diagnosis and the follow up of Acute Lymphoblastic Leukemia.
Study: NCT04418271

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation- new form of care
Description: The participants in the intervention group take part in a shared decision-making (SDM) conference to plan the intervention. The therapeutic content of the prehabilitation is defined individually for each patient in the SDM conference. Prehabilitation will be a structured and individually tailored 3-week program.
Study: NCT02330224

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypertension Management Intervention
Description: The multifaceted intervention consists of three main components:~1. Structured treatment algorithm with fixed dose antihypertensives for high cardiovascular disease risk patients~2. Motivational conversation by nurses and nurse practitioners for high risk patients at baseline~3. Telephone based follow-up for all patients by nurses
Study: NCT00806858

Intervention type: DEVICE
Intervention: NovoPen® 4
Description: Insulin administration by means of a NovoPen® 4 pen device
Study: NCT00401193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid tablets
Description: 3900 mg/Day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid tablets
Description: 1950 mg/Day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Study: NCT04135313

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 2000 mg/m2, bid, per os, days 1-14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 2000 mg/m2, bid, per os, days 1-14

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 130 mg/m2 iv day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m2 iv day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Pelvic radiotherapy dose: 44 Gy on regional nodes, 54 Gy on primary tumor in 2 Gy fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Pelvic radiotherapy dose: 44 Gy on regional nodes, 54 Gy on primary tumor in 2 Gy fractions

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rectal cancer surgery
Description: Laparoscopic or open total mesorectal excision or extralevator abdominoperineal resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rectal cancer surgery
Description: Laparoscopic or open total mesorectal excision or extralevator abdominoperineal resection
Study: NCT01206023

Intervention type: OTHER
Intervention: NA-NOSE artificial olfactory system
Description: NA-NOSE is an artificial olfactory system that is based on nanomaterials and connected with machine learning. NA-NOSE can diagnosis diseases or disorders based on volatile biomarkers that are emitted from exhaled breath, blood, or from clinical tissue.

Intervention type: OTHER
Intervention: NA-NOSE artificial olfactory system
Description: NA-NOSE is an artificial olfactory system that is based on nanomaterials and connected with machine learning. NA-NOSE can diagnosis diseases or disorders based on volatile biomarkers that are emitted from exhaled breath, blood, or from clinical tissue.
Study: NCT03571776

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Laparoscopic ovarian cystectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sclerotherapy
Description: US-aspiration and alcohol sclerosis
Study: NCT03476902

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapist assisted mobile intervention
Description: Individuals will receive 4 introductory sessions with a therapist followed by weekly phone calls. Participants will utilize nOCD application to assist with treatment protocol adherence.
Study: NCT00171158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Study: NCT01229319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm
Description: Cryotherapy alone to Left arm plus cryotherapy + imiquimod 3.75% daily x 2 weeks on and 2 weeks off and 2 weeks on to Right arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm
Description: Cryotherapy alone to Left arm plus cryotherapy + imiquimod 3.75% daily x 2 weeks on and 2 weeks off and 2 weeks on to Right arm
Study: NCT02666820

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Large balloon dilatation
Description: After biliary sphincterotomy was performed with full extension to the full length of transverse fold. A 12, 15, 18 or 20 mm CRE-balloon was passed over guide wire and position across the papilla. The balloon was gradually inflated to the largest size of the bile duct stone and/or the bile duct diameter. When complete stone removal was unsuccessful , crossing over treatment was considered at the discretion of the endoscopists.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical lithotripsy
Description: After biliary sphincterotomy was performed with full extension to the full length of transverse fold. A 3x6 cm Trapezoid Rx retrieval stone basket was used to capture the stone and crushing of stones was done when simple stone extraction failed to remove the stone. The stone fragments were then retrieved with a basket and/ or a retrieval balloon. When complete stone removal was unsuccessful , crossing over treatment was considered at the discretion of the endoscopists.
Study: NCT01980628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibrutinib
Study: NCT02731274

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular physical activity in Motor memory consolidation
Description: After the intervention, the assessment of the impact of exercise on motor memory consolidation was held in three stages: Training; 1 hour after training and 24 hours after training. For the analysis of the results, descriptive and inferential statistics were used.
Study: NCT00170274

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Activation of preventive and therapeutic algorithms for treatment of AF
Description: Algorithms in At 500 or Enrhyhtm for prevention and termination of Atrial Fibrillation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AF Prevention and Therapy Algorithms On
Description: Activation of AF-prevention and termination algorithms in AT 500 or EnRhyhtm
Study: NCT03484624

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treadmill walking
Description: All subjects underwent measurements of muscle fatigue and respiratory metabolism energy during treadmill walking at a comfortable speed for 6 minutes and measured by three conditions (①NoGEMS-free gait, ②Torque off with GEMS, and ③Torque on with GEMS)
Study: NCT01883739

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parental Presence at Handover Rounds
Study: NCT02287688

Intervention type: BIOLOGICAL
Intervention: Meningococcal quadrivalent CRM-197 conjugate vaccine
Description: This study is strictly observational. Decisions of vaccination are made by health care providers.
Study: NCT02603510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR342434
Description: Pharmaceutical form:solution~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR342434
Description: Pharmaceutical form:solution~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin lispro
Description: Pharmaceutical form:solution~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin lispro
Description: Pharmaceutical form:solution~Route of administration: subcutaneous
Study: NCT03351634

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of ACT balloon, Uromedica (Irvine, CA, USA) periurethrally at the bladder neck
Description: The ACT system is a permanent implant designed for the correction of incontinence in patients.
Study: NCT04140812

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: mass spectrometry (LC-MS/MS)
Description: Blood collection (5 drops) during newborn-screening (36-72h after birth) or postnatal hospitalization (\<36h after birth). The blood sample will then be examined using mass spectrometry (LC-MS/MS) for 125 proteins.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: mass spectrometry (LC-MS/MS)
Description: Blood collection (5 drops) during newborn-screening (36-72h after birth) or postnatal hospitalization (\<36h after birth). The blood sample will then be examined using mass spectrometry (LC-MS/MS) for 125 proteins.
Study: NCT02697916

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Description: 81mg of aspirin daily vs. 325mg of aspirin daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Description: 81mg of aspirin daily vs. 325mg of aspirin daily
Study: NCT00293800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%/Timolol 0.5% Ophthalmic Solution
Description: Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost 0.005% Ophthalmic Solution (XALATAN)
Description: Commercially marketed ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol 0.5% Ophthalmic Solution
Description: Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Timolol Vehicle
Description: Placebo
Study: NCT02100735

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sedation protocol
Description: Nursing driven sedation protocol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sedation protocol
Description: Nursing driven sedation protocol
Study: NCT01759719

Intervention type: DEVICE
Intervention: coronary angioplasty with PtCr stent implantation
Description: PCI with deployment of at least 1 PtCr stent
Study: NCT02309450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: .Asunaprevir, Daclatasvir and BMS - 791325
Description: All patients will receive an all-oral HCV tritherapy with Asunaprevir (200mg), Daclatasvir (30mg) and BMS-791325 (75mg) in a fixed-dose combination (FDC) tablet, twice a day (1 tablet in the morning and 1 tablet in the evening) for 12 weeks.
Study: NCT04170946

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Talazoparib in Combination with Low Dose Radiotherapy (RT)
Description: Dose escalation model to determine the safety and MTD of talazoparib in combination with low dose RT.
Study: NCT03972501

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZR-MD-001 Vehicle
Description: AZR-MD-001 is an ophthalmic ointment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZR-MD-001 Active Dose
Description: AZR-MD-001 is an ophthalmic ointment
Study: NCT04563637

Intervention type: DIAGNOSTIC_TEST
Intervention: Computer based vision application by video
Description: patients will be tested by computer based analysis of a video as well as by dexa scan.

Intervention type: RADIATION
Intervention: whole body dual energy x-ray absorptiometry scan
Description: subjects will receive a whole body dual energy x-ray absorptiometry scan to measure their body fat percentage
Study: NCT00349193

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: laquinimod 0.3
Description: laquinimod 0.3mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: laquinimod 0.6
Description: laquinimod 0.6mg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Blinded Placebo
Study: NCT04420247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: 5 days of treatment with Chloroquine + Standard Care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 5 days of treatment with Hydroxychloroquine + Standard Care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Description: Standard Care according to Brazilian Guidelines for treating COVID-19